ArticlePediatric transplantation2025
A 16-Year-Old with a Mycoplasma hominis Empyema Post-Lung Transplantation: A Case Report.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A 16-Year-Old with a Mycoplasma hominis Empyema Post-Lung Transplantation: A Case Report.Pediatric transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis is the first reported case of empyema due to Mycoplasma hominis in a pediatric transplant recipient.
methodsA 16-year-old Indigenous Canadian boy developed acute respiratory distress 29 days post-bilateral lung transplantation for chronic lung disease and pulmonary hypertension secondary to extreme prematurity and an atrial septal defect. Pre-transplant donor bronchial cultures grew Candida albicans and methicillin-sensitive Staphylococcus aureus, so he received 14 days of cefazolin. Post-transplant prophylaxis included azithromycin, voriconazole, micafungin, TMP-SMX, and valacyclovir. Immunosuppression included anti-thymocyte globulin induction, followed by tacrolimus, mycophenolate mofetil, and prednisone. The patient developed a large right pleural effusion over the course of 24 h requiring intensive care and high-flow supplemental oxygen. Pleural thoracentesis revealed a neutrophil-predominant exudative empyema. Routine cultures were negative; M. hominis was detected by PCR and specialized media. The patient completed 28 days of clindamycin and doxycycline and made an uneventful recovery.
resultsM. hominis and Ureaplasma species are donor-derived pathogens that can cause significant morbidity, including sternal wound infection, mediastinitis, pericarditis, and empyema. Post-lung transplant M. hominis infections occur in 2%-5% of cases. Diagnostic challenges, low clinical suspicion, and rising resistance contribute to poor outcomes and inappropriate antibiotic use. Although this patient's ammonia level was normal, hyperammonemia syndrome also remains a rare but serious complication of Ureaplasma urealyticum and M. hominis infections.
conclusionEarly screening, PCR testing, and prompt combination empiric therapy are crucial for improving outcomes in M. hominis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.